In a recent study presented at European Congress on Obesity, researchers found obesity drug semaglutide has similar effectiveness across different age groups with regard to weight loss (under 40 years, 40-60 years, and 60 years and over).
When looking at percentage body fat and lean body mass changes, semaglutide was found to have a more pronounced effect in patients aged under 50 years.
The study is from Tel Aviv University. One author is Dr. Dror Dicker.
Semaglutide was originally developed for and is also used to treat type 2 diabetes. However, its effects on weight loss led researchers to study its effect on weight loss in people living with obesity but without type 2 diabetes.
It is currently not approved for obesity anywhere in the world, however, new drug applications are under review by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other health agencies across the world.
Weight loss is often accompanied by loss of lean body mass, which can negatively impact physical functioning and/or resting energy expenditure. Bodyweight loss and body composition changes (fat mass vs lean mass) may differ by age.
In the study, the team tested the tolerability and effect of semaglutide 2.4 mg on weight loss and body composition according to age.
Adults without type 2 diabetes were assigned to a once-weekly injection of semaglutide 2.4 mg or placebo, both plus lifestyle intervention, for 68 weeks.
The team found that change in body weight (%) was greater for semaglutide than for placebo and was consistent across age groups:
40 years and under mean weight loss 15.2% semaglutide group versus 2.3% placebo; 40-60 years 14.6kg semaglutide versus 2.5kg placebo; and 60 years and over 14.7kg semaglutide versus 2.4kg placebo.
The changes in lean: fat mass ratio were found to be more pronounced in those patients under 50 years—the authors suggest the metabolic effects of aging could be behind this difference.
The safety of semaglutide was generally consistent across age groups. Gut disorders were the most commonly reported adverse events across all age groups.
The team says the treatment with semaglutide reduced body fat mass and increased lean body mass in all participants, which was more pronounced in those aged under 50 years.
Semaglutide was generally well tolerated irrespective of age.
If you care about obesity and your health, please read studies about this popular ingredient in food may increase your diabetes and obesity risk and findings of eating this food everyday may help prevent weight gain and obesity.
For more information about weight loss, please see recent studies about obesity linked to abnormal bowel habits—not diet and results showing that a new way to prevent, even reverse obesity.
Copyright © 2021 Knowridge Science Report. All rights reserved.
